SLC5A2 and type 2 diabetes mellitus: The study's lead researcher, Dr. Benjamin Horne, hypothesized the process of intermittent fasting might be similar to SGLT-2 inhibitors in lowing the risk factors for heart failure and type 2 diabetes [49].